# Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06384352/  
OnCo record `nct06384352` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of YL211 alone in advanced solid tumours and with pembrolizumab in non-squamous non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06384352 by MediLink Therapeutics (Suzhou) Co., Ltd., with Hoffmann-La Roche as collaborator; 500 participants are planned, it started on 2024-05-01; the registry gives 2031-06-30 as its primary completion date. Interventions recorded: YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin). Conditions listed: Advanced Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06384352
- Phase: 1
- Setting: A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT06384352: https://clinicaltrials.gov/study/NCT06384352

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [YL211](https://onco.cc/drugs/yl211/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct06384352.json